Dendreon's press releases over the past year are seemingly filled with nothing but bad news. Investors suffered another gut punch today, as shares plummeted 23% amid declining Provenge sales -- but also in the face of a significant operational shake-up that should let the company more easily break even. Watch health-care editor and analyst David Williamson break down what these events mean for investors.
Many investors are attracted to biotechs like Dendreon, since they hold the allure of substantial short-term gains. But there is more than one approach to building long-term wealth and retiring well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.
The article Can Dendreon Be Saved? originally appeared on Fool.com.
David Williamson owns shares of Johnson & Johnson and Dendreon, but he holds no other position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson and creating a diagonal call position in Johnson & Johnson. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.